Mammalian Cell Line Development

AbZelectPRO™ is our enhanced CHO-K1 cell line development platform, offering high yields and rapid progression from DNA to RCB in 10 weeks. Our GS Knockout (KO and KO+) technologies further enhance stability and efficiency, de-risking the IND journey.

Our AbZelectPRO™ platform supports efficient, stable production of both traditional and difficult-to-express therapies such as fusion proteins, bispecifics, and other novel modalities by combining ProteoNic’s 2G UNic® premium vector technology with a CHO host cell line. Further enhanced with our GS Knockout (KO and KO+) systems, it features a unique double promoter to drive gene expression and mRNA stability, achieving higher viable cell density and productivity than other platforms.

Our AbZelectPRO™ platforms are designed to provide the flexibility needed to support your unique antibody-based therapy, whether that’s a monoclonal antibody (mAb), bispecific antibody, fusion protein or a novel modality. Leveraging our analytical development and regulatory expertise, we can adapt our testing methods or develop new assays to safeguard the quality of your therapy from CLD to manufacturing.

For standard IgG mAbs, Abzena can reach titres up to 10 g/L at the ambr15 clonal assessment stage, with research cell banks ready in as little as 10 weeks from transfection.

Abzena uses a random integration approach, which delivers stable, high-yielding clonal lines comparable to transposase methods. Our capability is further enhanced with our two new GS Knockout cell lines. We guide clients toward context-driven CLD decisions. Our findings empower drug developers to reconsider assumptions and embrace the method best suited for their molecule, timeline, and budget. Please download our detailed whitepaper including recent case studies following the link below.

Abzena’s CLD platform has advanced more than 20 programs into the clinic. With proven performance, more than 90 INDs and four marketed drugs.

Efficient tech transfer is a common area of focus when relying on a contract development and manufacturing organization (CDMO) for support, being critical for the smooth transition of projects from CLD into manufacturing. Operating across our sites in Cambridge, UK, and San Diego, US, our teams work closely together to ensure the seamless progression of your project. Our extensive experience and collaborative culture allow us to proactively identify and prevent risks that could delay your therapy reaching patients.